Revenue growth of 20% with 35% EBITDA growth at a 34-36% EBITDA margin in FY25. Doubling revenue to Rs 1,000 cr during FY24-27 at a CAGR of 21%. . Maintaining EBITDA margin of 28-30%
Share this post
Supriya Lifescience: PAT growth of 67% …
Share this post
Revenue growth of 20% with 35% EBITDA growth at a 34-36% EBITDA margin in FY25. Doubling revenue to Rs 1,000 cr during FY24-27 at a CAGR of 21%. . Maintaining EBITDA margin of 28-30%